Tag: HCV

Hepatitis C virus (HCV) can infect the liver, causing inflammation that injures this organ. If HCV is left untreated, injury can spread throughout the liver and this organ consequently becomes increasingly dysfunctional. As a result, the eventual appearance of serious symptoms related to liver damage occurs and a person’s quality of life degrades. HCV infection… Read more »

Update on PHAC’s HIV and Hepatitis C Activities

Under the Federal Initiative to Address HIV/AIDS in Canada and the Hepatitis C Prevention, Support and Research Program, the Agency currently manages separate funding programs to support the community response to HIV and hepatitis C. The projects under these programs are in the process of being extended for three years, from April 1, 2014 –… Read more »

CATIE HepCinfo Update 5.5

6 week treatment cures almost all “hard to treat” participants A six-week treatment of sofosbuvir (Sovaldi), ledipasvir and a third drug cured a majority of people with genotype 1 Hep C virus who had never been treated before, according to research presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston…. Read more »

CATIE’s HepCInfo Update 5.4

New and Noteworthy European Medicines Agency advises on compassionate use of sofosbuvir (Sovaldi) and ledipasvir The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the compassionate use of sofosbuvir (Sovaldi) and ledipasvir for people with hepatitis C who are at high risk of liver failure or death within 12 months…. Read more »

Spring update from PHCN

This last month has been a whirlwind of symposiums, conferences and meetings.  We learned and shared a lot during our time spent with colleagues and collaborators across the country.  At the PAN ‘Effective Interventions’ conference in Vancouver, we presented on the benefits of the Community Readiness Model.   In Toronto, we presented about the patient experience… Read more »

According to researchers, the main causes of persistent liver disease include: chronic hepatitis B virus (HBV) infection chronic hepatitis C virus (HCV) infection alcoholic liver disease (ALD) non-alcoholic fatty liver disease (NAFLD) autoimmune liver disease Regardless of the instigator of chronic liver disease, liver damage usually proceeds along a common route, causing chronic inflammation, the… Read more »

From CATIE: Top 10 HIV and Hep C Research News from 2013

Original posted on CATIE. Top 10 HIV and Hep C Research News from 2013 What were the most notable HIV and hepatitis C research stories from 2013? We’ve listed the top 10 stories from CATIE News below.   1. New evidence-based approaches to HIV and hepatitis C From national guidelines for HIV testing to best… Read more »

  In December 2013,  Health Canada approved Sovaldi (sofosbuvir) for use in Canada. As a new HCV treatment drug, sofosbuvir offers great promise  for shorter treatment times, and the convenience of taking one pill a day. This new treatment  drug has the potential to be effective without interferon (depending on genotype) however, treatment still involves… Read more »

CATIE’s HepCinfo Update 4.24

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:”Table Normal”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:””; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”;} New and Noteworthy New study estimates cases of hepatitis B and C, but experts warn figures may be too low A new federal government… Read more »

CATIE HepCinfo Update 4.22

New and Noteworthy FDA advisory committee recommends the approval of simeprevir and sofosbuvir The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously recommended the approval of two direct-acting antivirals for hepatitis C, simeprevir and sofosbuvir. The newer direct-acting antiviral medications are more effective, easier to take and have significantly fewer… Read more »

Germs such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infect and injure the liver. Long-term or chronic infection with either of these viruses can cause inflammation and healthy liver tissue is replaced with useless scar tissue. Prolonged increased levels of liver enzymes in the blood occur, suggestive of ongoing liver injury. Gradually… Read more »